NC
IOVA icon

nVerses Capital’s Iovance Biotherapeutics IOVA Stock Holding History

nVerses Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,420
Closed -$82.2K – 423
2026
Q1 		$82.2K Buy
+23,420
New +$74.9K 0.07% 330
2024
Q4 		– Sell
-15,800
Closed -$148K – 422
2024
Q3 		$148K Buy
+15,800
New +$150K 0.07% 396

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

nVerses Capital's IOVA Position: Q2 2026 in Review

nVerses Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 23,420 shares — an estimated $82.2K sold.

nVerses Capital first reported a position in IOVA in Q3 2024 and held it in 2 quarters. The position peaked at $148K in Q3 2024. 216 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • nVerses Capital reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 23,420 Iovance Biotherapeutics shares in Q2 2026, an estimated $82.2K.
  • nVerses Capital first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's Iovance Biotherapeutics position peaked at $148K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.